NASDAQ:LXEO Lexeo Therapeutics Q4 2025 Earnings Report $3.52 -0.55 (-13.51%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$3.44 -0.08 (-2.16%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Lexeo Therapeutics EPS ResultsActual EPS-$0.27Consensus EPS -$0.32Beat/MissBeat by +$0.05One Year Ago EPSN/ALexeo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALexeo Therapeutics Announcement DetailsQuarterQ4 2025Date3/30/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Lexeo Therapeutics Earnings HeadlinesApertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich AtaxiaSeptember 23 at 8:00 AM | prnewswire.comLexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic ForumSeptember 23 at 7:00 AM | globenewswire.comArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.25 g/t. After roughly 21,000 metres of drilling, the company is closing in on its first-ever mineral resource estimate, expected in Q3 or Q4 2026. That estimate could offer the market its first real look at the scale of this emerging gold system.September 24 at 1:00 AM | Wall Street Logic (Ad)Lexeo Therapeutics, Inc. agreed to acquire Mantle Therapeutics Inc. for $21.3 million .September 22 at 12:33 AM | marketscreener.comMLexeo Therapeutics to Acquire Mantle Therapeutics for Up to $21.3 Million; Enters Three Research CollaborationsSeptember 22 at 12:33 AM | finance.yahoo.comLexeo Therapeutics Signs Series Of Strategic Transactions To Expand Presence In Friedreich AtaxiaSeptember 22 at 2:32 PM | rttnews.comSee More Lexeo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lexeo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexeo Therapeutics and other key companies, straight to your email. Email Address About Lexeo TherapeuticsLexeo Therapeutics (NASDAQ:LXEO) is a clinical-stage biotechnology company focused on developing gene therapies for genetic and acquired diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material intended to address underlying disease mechanisms, with programs spanning central nervous system and cardiovascular conditions. Lexeo’s development portfolio includes investigational therapies for APOE4-associated Alzheimer’s disease, Friedreich’s ataxia, and inherited cardiac disorders such as LMNA-related dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. Its candidates are in clinical development, and the company’s research and development activities are primarily focused on advancing these therapies through clinical testing and regulatory evaluation. Founded in 2017 and headquartered in New York, Lexeo serves patients through a development program centered largely on the United States. The company is led by Chief Executive Officer R. Nolan Townsend and became a publicly traded company on the Nasdaq under the ticker symbol LXEO in 2023.View Lexeo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
